Are there any specific dosage modifications for cosentyx in patients with liver disease?

Are there any Cosentyx (secukinumab) dose changes needed for liver disease?

No specific liver-disease dosage modifications for Cosentyx are described in the provided information. Cosentyx’s dosing guidance focuses on the prescribed dosing regimen for the condition being treated, without separate adjustment instructions for hepatic impairment.

Does Cosentyx guidance mention hepatic impairment anywhere else?

The provided information does not include any hepatic impairment-specific dosing instructions (such as dose reductions, dose spacing changes, or contraindications) for Cosentyx.

What should clinicians check if a patient has liver disease anyway?

Even without explicit liver-dosing changes, clinicians typically confirm:
- the patient’s current disease severity and liver function status,
- other medications the patient is taking that may affect the liver,
- and whether any Cosentyx-specific monitoring or precautions are referenced in the full prescribing information for their region.

If you share the country/label you’re using (for example, U.S. FDA label vs. EU SmPC) or paste the relevant section, I can interpret the exact language on hepatic impairment and dosing from that source.